<div id=toc></div>

# Table of Contents

- [q-bio.MN](#q-bio.MN) [Total: 1]
- [cs.LG](#cs.LG) [Total: 1]


<div id='q-bio.MN'></div>

# q-bio.MN [[Back]](#toc)

### [1] [Using stationary information flows to prove kinetic uncertainty relations in biochemical control systems](https://arxiv.org/abs/2512.20887)
*Ryan Ripsman,Brayden Kell,Andreas Hilfinger*

Main category: q-bio.MN

TL;DR: 论文证明了生化系统中反馈控制的基本限制：要减少某个组分的丰度波动，必须至少有一个牺牲组分承受更大的变异性，这是任意反应网络的普遍规律。


<details>
  <summary>Details</summary>
Motivation: 细胞组分常以低拷贝数存在，随机生产降解事件导致显著丰度波动。虽然反馈控制理论上能抑制这种波动，但先前研究推测存在基本性能限制：减少一个组分的波动需要至少一个牺牲组分承受更大变异性。本文旨在严格证明这一普遍规律。

Method: 基于分子丰度间互信息率的概率电流分解，提出精确且通用的数学证明方法。该方法适用于任意大小和结构的反应网络。

Result: 成功证明了先前推测的普遍规律：在任意生化反应网络中，要降低某个组分的丰度波动，必须至少有一个其他组分承受更大的变异性。这为生化反馈控制建立了基本限制。

Conclusion: 细胞组分的变异性是细胞控制的必要条件。波动组分不一定是"噪声"源，而可能是参与消除其他组分"噪声"的控制分子。这一发现改变了我们对细胞波动功能的理解。

Abstract: Many cellular components are present in such low numbers that individual stochastic production and degradation events lead to significant fluctuations in molecular abundances. Although feedback control can, in principle, suppress such low-copy-number fluctuations, general rules have emerged that suggest fundamental performance constraints on feedback control in biochemical systems. In particular, previous work has conjectured that reducing abundance fluctuations in one component requires at least one sacrificial component with increased variability in arbitrary reaction networks of any size. Here, we present an exact and general proof of this statement based on probability current decompositions of mutual information rates between molecular abundances. This suggests that variability in cellular components is necessary for cellular control and that fluctuating components do not necessarily generate cellular "noise" but may correspond to control molecules that are involved in removing "noise" from other cellular components.

</details>


<div id='cs.LG'></div>

# cs.LG [[Back]](#toc)

### [2] [Transcriptome-Conditioned Personalized De Novo Drug Generation for AML Using Metaheuristic Assembly and Target-Driven Filtering](https://arxiv.org/abs/2512.21301)
*Abdullah G. Elafifi,Basma Mamdouh,Mariam Hanafy,Muhammed Alaa Eldin,Yosef Khaled,Nesma Mohamed El-Gelany,Tarek H. M. Abou-El-Enien*

Main category: cs.LG

TL;DR: 开发了一个端到端计算框架，通过整合转录组学、结构建模和进化算法，为急性髓系白血病患者生成个性化药物先导化合物


<details>
  <summary>Details</summary>
Motivation: 急性髓系白血病（AML）由于分子异质性高、复发率高，临床治疗面临挑战。精准医学虽然引入了突变特异性疗法，但许多患者仍缺乏有效的个性化治疗选择。需要开发能够连接患者特异性转录组学和新药发现的创新方法。

Method: 1. 使用TCGA-LAML队列的RNA测序数据，通过加权基因共表达网络分析（WGCNA）筛选出20个高价值生物标志物；2. 使用AlphaFold3对这些靶点的物理结构进行建模；3. 通过DOGSiteScorer引擎定量映射可药物化热点；4. 开发了反应优先的进化元启发式算法和多目标优化程序，从片段库组装新型配体；5. 通过ADMET分析和SwissDock分子对接进行验证。

Result: 1. 鉴定了包括HK3和SIGLEC9在内的20个高价值生物标志物；2. 生成模型产生了结构独特的化学实体，QED评分在0.5-0.7之间，表明药物相似性良好；3. 验证发现了高置信度候选化合物，如配体L1对A08A96生物标志物的结合自由能为-6.571 kcal/mol；4. 框架成功整合了系统生物学和元启发式分子组装。

Conclusion: 整合系统生物学与元启发式分子组装能够产生药理学上可行、患者定制的先导化合物，为AML及其他疾病的精准肿瘤学提供了可扩展的蓝图。该方法展示了计算框架在个性化药物发现中的潜力。

Abstract: Acute Myeloid Leukemia (AML) remains a clinical challenge due to its extreme molecular heterogeneity and high relapse rates. While precision medicine has introduced mutation-specific therapies, many patients still lack effective, personalized options. This paper presents a novel, end-to-end computational framework that bridges the gap between patient-specific transcriptomics and de novo drug discovery. By analyzing bulk RNA sequencing data from the TCGA-LAML cohort, the study utilized Weighted Gene Co-expression Network Analysis (WGCNA) to prioritize 20 high-value biomarkers, including metabolic transporters like HK3 and immune-modulatory receptors such as SIGLEC9. The physical structures of these targets were modeled using AlphaFold3, and druggable hotspots were quantitatively mapped via the DOGSiteScorer engine. Then developed a novel, reaction-first evolutionary metaheuristic algorithm as well as multi-objective optimization programming that assembles novel ligands from fragment libraries, guided by spatial alignment to these identified hotspots. The generative model produced structurally unique chemical entities with a strong bias toward drug-like space, as evidenced by QED scores peaking between 0.5 and 0.7. Validation through ADMET profiling and SwissDock molecular docking identified high-confidence candidates, such as Ligand L1, which achieved a binding free energy of -6.571 kcal/mol against the A08A96 biomarker. These results demonstrate that integrating systems biology with metaheuristic molecular assembly can produce pharmacologically viable, patient tailored leads, offering a scalable blueprint for precision oncology in AML and beyond

</details>
